# Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

> **NCT02730299** · PHASE3 · COMPLETED · sponsor: **Gamida Cell ltd** · enrollment: 125 (actual)

## Conditions studied

- Hematological Malignancies
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
- Chronic Myelogenous Leukemia (CML)
- Myelodysplastic Syndrome (MDS)
- Lymphoma
- Acute Leukemia

## Interventions

- **DRUG:** NiCord® (omidubicel)
- **OTHER:** Cord Blood Unit

## Key facts

- **NCT ID:** NCT02730299
- **Lead sponsor:** Gamida Cell ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-16
- **Primary completion:** 2021-04-29
- **Final completion:** 2025-02-07
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02730299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02730299, "Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02730299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*